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1. Introduction 
Antiphospholipid syndrome (APS) is an autoimmune multisystemic disorder characterized 
clinically by recurrent thrombosis and pregnancy morbidity and serologically by the 
presence of antiphospholipid antibodies (aPL) including anticardiolipin (aCL) and anti-2 
glycoprotein I (anti-2GPI) antibodies and lupus anticoagulant (LA) [1]. 
Historically, aPL antibodies were classified based on the clinical laboratory test in which 
they were detected, i.e. LA and aCL antibodies. It is now widely accepted that aPL 
antibodies are a heterogenous group of antibodies that react with a myriad of phospholipids 
(PLs), PL-protein complexes and PL binding proteins. The main antigenic target of these 
antibodies is recognized to be 2glycoprotein I (2GPI), which along with prothrombin 
accounts for more than 90% of the antibody binding activity in APS patients. Other 
potentially significant antigenic targets include tissue plasminogen activator (tPA), 
phosphatidylserine (PS), plasmin, annexin 2, activated protein C (APC), thrombin, 
antithrombin (AT) and annexin A5 [2,3].  
In the general population, APS is the most common cause of acquired thrombophilia and is 
a recognized risk factor for the development of deep vein thrombosis (DVT) with or without 
pulmonary embolism, new strokes in individuals below the age of 50 and recurrent fetal loss 
[4]. The prevalence of DVT occurrence in the general population is estimated at 2-5%, 15 -
20% associated with APS, suggesting that the prevalence of venous thrombosis associated 
with APS may be as high as 0.3-1% of the general population [4]. APL antibodies are present 
in 30-40% of systemic lupus erythematosus (SLE) patients and up to a third of these patients 
(10-15% of SLE patients) have clinical manifestations of APS, especially venous or arterial 
thromboses [5,6].  
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The APS related thrombotic events range in severity from the relatively benign superficial 
thromophlebitis to myocardial infarction, stroke and catastrophic APS (CAPS) [7]. APS also 
accounts for a significant proportion of recurrent pregnancy loss in SLE patients, indeed, 
aPL are now regarded as the most frequent acquired risk for a treatable cause of recurrent 
pregnancy loss and for pregnancy complications (early and severe pre-eclampsia) [5,8]. 
The first description of aPL antibodies dates back to 1952, when Moore et al described 
patients suffering from SLE with a persistently false positive VDRL flocculation test for 
syphilis, a test based on the detection of antibodies against cardiolipin (CL) extracted from 
beef heart [7]. In the same year, Conley et al [8,9] described two SLE patients with a peculiar 
circulating inhibitor of coagulation [10]. These “anticoagulants” could inhibit in vitro 
coagulation assays, but did not influence the activity of coagulation factors and were not 
associated with a bleeding diathesis. Feinstein and Rapaport introduced the term LA to 
describe this phenomenon in 1972 [10]. Although the relation between thrombosis and the 
presence of these anticoagulants in SLE patients was already noticed in 1963 [11], it took 
until 1980 before the association between LA and thrombosis was widely recognized [12]. 
As LA was found to be associated with a persistently false positive syphilis test, this led to 
the development of an aCL immunoassay and the establishment of the association between 
thrombosis and aCL anticardiolipin [13]. From this time on, patients presenting with 
thrombosis and/or pregnancy loss in combination with persistently positive aCL antibodies 
and/or circulating LA were considered to have the APS [14,15]. Subsequently, patients with 
systemic lupus erythematosus (SLE) and related connective tissue diseases (CTD) that had 
abnormal LA tests, were labeled as ‘secondary’ APS (SAPS) in the presence of these 
conditions and ‘primary’ (PAPS) in their absence [16]. A study of patients with SLE showed 
that aCL positivity preceded the onset of a more severe form of SLE, as well as SLE 
complicated with thrombosis, pregnancy loss and thrombocytopenia [5]. However, studies 
have found no difference between PAPS and SAPS with respect to the clinical 
complications, the timing of those complications, the prognosis or frequency of positive 
aCL, LA or other autoantibody tests. In addition, management of PAPS and SAPS is the 
same and prognosis does not appear to differ [17]. 
2. Traditional and non-traditional manifestations of APS 
APS is classically characterized by vascular thromboses or obstetric morbidity in association 
with the presence of aPL antibodies [1]. Vascular thromboses include venous thromboses 
resulting clinically in deep venous thrombosis and/or pulmonary emboli while arterial 
thromboses may present with ischemia affecting limbs, cerebral vascular accidents or 
transient ischemic attacks and small-vessel thrombosis may result in cutaneous ulceration 
[1,18]. Presence of thrombosis should be confirmed with a diagnostic angiogram, Doppler 
ultrasound, pulmonary scintigraphy, histopathology or computed tomography (CT) or 
magnetic resonance imaging (MRI) of the brain depending on the clinical context [1].  
In a longitudinal cohort of patients with APS, transient ischemic attacks (TIA)s and 
cerebrovascular accidents (CVA)s were the most common thrombotic events occurring in 
2.4% and 2.3% respectively of patients with established APS followed by pulmonary 
embolism and deep venous thrombosis over a period of 5 years [18]. 
Obstetric manifestations of APS include fetal loss with loss after 10 weeks of gestation 
being more strongly associated with APS, placental insufficiency potentially resulting in 
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decreased gestational weight or fetal distress and preterm delivery and development of 
pre-eclampsia and frank eclampsia [1]. Early pregnancy loss occurs in 17.1% and late 
pregnancy loss occurs in 6.7% of pregnancies in women with established APS while 35% 
of successful pregnancies were premature and 13.7% had intrauterine growth restriction 
[18].  
Catastrophic APS (CAPS) is the rare but life-threatening development of wide-spread 
intravascular thrombosis seen in less than 1% of patients with APS [18-20]. Patients present 
acutely with multi-organ system failure, evidence of small vessel thrombosis and presence 
of positive aPL antibodies [19,20]. Death occurs in approximately 45% of patients during the 
acute event with primary causes being cerebral involvement, cardiac involvement, 
infections, multiorgan failure, pulmonary involvement and abdominal involvement [20]. 
Infection is the most common trigger identified in CAPS being present in approximately 
20% of patients [20]. 
Patients with APS may also develop manifestations not included in the classification criteria. 
Neurologic symptoms other than strokes or TIAs including chorea, dementia, transverse 
myelitis, multiple sclerosis and epilepsy have been attributed to APS although studies are 
contradictory [1,18,21]. Livedo reticularis occurs more commonly in APS and may progress 
to livedo vasculitis with purpuric lesions, nodules and painful ulcerations [1,18,22]. Presence 
of livedo reticularis appears to carry an increased risk of arterial thrombosis, CVA and 
pregnancy loss [22]. 
Thrombocytopenia is the most common hematologic manifestation, occurring in over 30% of 
patients with APS [22]. Cardiac involvement frequently manifests as valvular disease with 
presence of mitral or tricuspid valve thickening or regurgitation and presence of valvular 
vegetations [19]. APS is also associated with a thrombotic microangiopathy of the renal 
arterioles and glomeruli known as APS nephropathy, which leads to hypertension, 
nephrotic range proteinuria, hematuria and progressive renal insufficiency [1].  
3. Current diagnostic algorithms 
a. “Criteria” aPL tests.  
Current classification criteria for definite APS require the use of three “standardized” 
laboratory assays to detect aPL antibodies. These assays include aCL, both IgG and/or IgM 
by enzyme-linked immunosorbent assay (ELISA), the anti-2GPI IgG and/or IgM by ELISA 
and the LA [1]. These tests, when positive, represent criteria for diagnosis when at least one 
of the two major clinical manifestations (thrombosis or pregnancy losses) is present 
according to the revised Sapporo criteria (Table 1).  
Laboratory testing for aPL antibodies is one of the most problematic areas in the field of 
APS. The confirmation of diagnosis of the APS relies on laboratory tests, since clinical 
manifestations such as thrombosis and pregnancy losses may occur for many reasons not 
related to the presence of aPL antibodies. Most importantly, patients with APS who have 
experienced thrombosis and/or pregnancy losses need a specific therapy that is often life-
long and must be personalized, requiring careful monitoring of additional risk factors to 
prevent recurrences of APS manifestations. Given the potential serious side effects of 
anticoagulant therapy, a solid diagnosis is essential in planning management. 
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a)Lupus anticoagulant 
(LAC) 
Positive on two or more occasion at least 12 weeks apart, 
detected according to the guidelines of ISTH 
b)Anticardiolipin (aCL) 
antibody 
Positive for IgG or IgM isotype in serum or plasma, present in 
medium and high titer on two or more occasions, at least 12 
weeks apart, measured by standardized ELISA. 
c)Anti-2GPI antibody Positive for IgG or IgM isotype (in titer > the 99th percentile) on 
two or more occasions, at least 12 weeks apart measured by 
standardized ELISA 
Miyakis et al J Thromb Haemost 2006; 4; 295-306. 
Table 1. Laboratory Criteria for APS (Revised Sapporo Criteria). 
Although international consensus guidelines for the determination of LA have been 
published and revised, the existence of “standardized” tests for detection of aCL and anti-
2GPI has remained elusive. Furthermore, despite over 7000 publications related to the 
clinical use of aPL antibody tests, a consensus on clinical recommendations has been 
difficult to achieve. This difficulty appears related to sub-optimal design in clinical studies 
and a lack of laboratory standardization in areas such as the following: 1) units of 
measurement, 2) calibration curves, 3) determination of cut-off values, and 4) laboratories 
not performing the tests according to established guidelines. Significant inter-assay and 
inter-laboratory variation in the results of both aCL and anti-┚2GPI testing still exists, 
affecting the consistency of the diagnosis of APS [23]. 
Over the years, international workshops have worked hard to standardize the laboratory 
test in this area. These workshops include the APL European forum, the Australasian 
Anticardiolipin Working Party (AAWP), the College of American Pathologists (CAP), the 
National External Quality Assessment Scheme (NEQAS), and the Standardization 
Subcommittee (SSC) on lupus anticoagulant and phospholipid-dependent antibodies of the 
International Society of Thrombosis and Hemostasis (ISTH). While some laboratories can 
obtain reliable testing results, there is still wide inter-laboratory variation despite all the 
efforts at standardization. This situation may result from laboratories performing aPL assays 
with their own protocols or using commercial kits that do not conform to the proposed 
guidelines for these tests. Furthermore, standardization of tests or re-evaluation of 
standardization is important since APS is related to serious complications like thrombosis 
and pregnancy loss; missing a diagnosis because of laboratory variability could have serious 
medical consequences. The use of semi- or fully-automated analyzers and commercial kits 
instead of in-house assays poses additional challenges to the process of standardization [23]. 
To address the challenges on aPL testing described above, an international “Criteria aPL Task 
Force” (Task Force) of researchers and scientific leaders in the field was formed prior to the 
13th International Congress on Antiphospholipid Antibodies in Galveston, TX, April 2010 
(APLA 2010). The “Criteria” aPL Task Force was further divided into three subgroups, 
which were charged by the APLA 2010 Congress Chair to address, in an evidence-based 
manner, various topics related to the testing of aCL, anti-┚2GPI and LA. To accomplish its 
mission, the Criteria aPL Task Force considered published information, the results of a 
survey distributed among APLA 2010 congress attendees and the discussions that occurred 
during a special preconference workshop at APLA 2010. On the basis of this approach, the 
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Task Force reached several conclusions and proposed recommendations discussed below 
and summarized in Table 2; this information has recently been published [24-26]. 
 
Subgroup1 
International Consensus 
Guidelines on assay 
performance of aCL and 
anti-2GPI assay. 
Conclusions 
Development of International Consensus Guidelines for aCL 
and anti-2GPI assays including pre-analytical, analytical and 
post-analytical considerations. 
 
(Lakos G et al. Arthritis Rheum 2011 Sep 27. doi: 10.1002/art.33349) 
Subgroup 1 
Guidelines on use of 
calibrator for aCL/ anti-
2GPI assays and 
selection and preparation 
of reference material 
Conclusions: 
a) Tests to be reported in GPL/MPL units if monoclonal 
antibodies are used as a calibrator.  
b) Levels of secondary calibrators should be meticulously 
defined prior to use. 
c) Evaluation of the performance of various monoclonal and 
polyclonal antibodies in order to identify optimal material for 
standardization.  
d) Establishment of international units for measurement for anti-
2GPI antibodies (work in progress) 
 
(Pierangeli S et al. Clin Chim Acta. 2011 Oct 15. [Epub ahead of 
print]) 
Subgroup 2 
Review of the Updated 
ISTH SCC guidelines on 
the use of Lupus anti- 
coagulant (LAC) for 
diagnosis. 
Conclusions: 
a) Weak LAC does not predict behavior in vivo. 
b) Consideration of false-positive results with the use of 
phospholipid –diluting agent. 
c) Additional lab testing to differentiate LAC from factor 
inhibitors, if clinically indicated. 
d) An inter-laboratory study to validate the statement about 
integrated test and not requiring performance of “mixing” tests 
e) LAC to be tested 2-3 weeks after warfarin discontinuation  
f) Clinicians to contact reference laboratories to discuss specific 
issues related to LAC and results interpretation.  
Subgroup 3 
Role of aPL as “risk 
factors”.  
Conclusions:  
a) Develop collaborations with existing large, population-based, 
prospective cohorts with available data on thrombosis and/or 
pregnancy outcomes to examine the value of aPL-SCORE.  
b) Full panel of currently available aPL test should be performed 
and if possible new tests like anti- PS/PT, anti-2GPI domain I, 
annexin A5 should also be evaluated 
Table 2. “CRITERIA” aPL Task Force Recommendations.  
b. “Non-Criteria” aPL Tests.  
As indicated above, the revised classification criteria for the diagnosis of APS include the 
positivity of at least one of the three ‘Criteria’ aPL tests [1]. However, the use of these tests 
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may not guarantee full sensitivity and specificity to confirm a diagnosis of APS. In clinical 
practice, there are indeed many ‘false positives’ with aPL tests, especially the aCL ELISA, 
which can give positive results in clinical conditions besides APS; these conditions include 
infectious disease (i.e., syphilis), malignancy and other autoimmune diseases. On the other 
hand, there are patients with a clinical pattern strongly suggestive of APS, but persistently 
negative for ‘Criteria’ tests. In addition the “criteria” aPL tests may not identify the 
“pathogenic” subpopulations of aPL.  
Several autoantibodies have been demonstrated to bind directly to negatively charged 
phospholipids other than CL (individually or as a phospholipid mixture) or to other 
proteins in the coagulation cascade (i.e., prothrombin and/or phosphatidylserine-
prothrombin complexes); antibodies can also interfere with anticoagulant activity of the 
annexin A5. However, the clinical and diagnostic utility of these newly developed assays as 
well as their standardization requires much further study. In some cases, these new assays 
lack standardization and there are not international units of measurements.  
A “Non-Criteria” aPL Task Force assembled prior to APLA 2010 was charged by the 
Congress Chair to address, in an evidence-based manner, the status of various new tests 
being developed for confirmation of diagnosis of APS. The results and recommendations of 
that task force have been recently published elsewhere [27]. 
4. Antigenic targets of antiphospholipid antibodies: Phospholipids and 
phospholipid binding proteins 
As stated previously, aPL represent a heterogenous group of antibodies with reactivity to 
not only PLs but also proteins, in particular those able to bind and form complexes with PLs 
[2]. Historically, serological activity against cardiolipin (CL) (Figure 1a), an anionic PL found 
in mitochondrial membranes, was one of the earliest key descriptive features of APS and 
although still important is overshadowed by 2GPI, which is now recognized as the main 
antigenic target of pathogenic aPL [2]. Indeed, 2GPI along with prothrombin (PT) account 
for more than 90% of the antibody binding activity in APS patients and it is unsurprising 
that antibodies against these 2 abundant proteins involved in hemostasis are most 
consistently associated with LA activity [28]. 2GPI consists of five contiguous domains 
(Figure 1b), the first proposed to be the binding site for pathogenic anti-2GPI antibodies 
and the fifth the binding site for anionic and hydrophobic phospholipids such as 
phosphatidylserine (PS), lyso (bis) phosphatidic acid (LBPA), and CL exposed on cell 
surfaces and protein receptors [2,29]. The role that apoptosis plays in the exposure of these 
phospholipids on the cell surface and the subsequent interaction with 2GPI has been 
proposed as a possible mechanism for the production of pathogenic aPL in APS patients 
[30]. An interesting pathogenic role for oxidized low-density lipoprotein (ox-LDL)/2GPI 
complexes bound by aPL in the initiation and progression of atherogenesis has been 
described [31,32]. 
Several models have been put forward for pathogenic anti-2GPI Abs complexed with 2GPI 
activating monocytes, ECs, trophoblasts and platelets via simultaneous binding to PLs and 
candidate protein receptors to induce production of tissue factor and proinflammatory 
cytokines [33-36]. In vivo and in in vitro studies have demonstrated the role of annexin  
A2 (AnnA2), in association with Toll-like receptor 4 (TLR4) and/or apolipoprotein ER2’  
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Pierangeli et al.  
Fig. 1. Schematic representation of Cardiolipin and of ┚2Glycoprotein I. 
A. Cardiolipin structure contains 2 negatively charged phosphate head groups, 3 glycerol 
moieties and 4 fatty acyl chains 
B. ┚2-glycoprotein I structure consists of 5 contiguous sushi domains. The first 4 consisting 
of 60 amino acids and the fifth consisting of 80 amino acids and more positive charged 
amino acids 
(ApoER2’) that act as co-receptors containing intracellular signaling domains, in the 
activation of ECs, monocytes and cells of the decidua and trophoblast [37-39]. Candidate 
receptors on platelets include ApoER2’ and the glycoprotein Ib (GPIb) subunit of the 
GPIb-V-IX receptor and Sikara et al have demonstrated a putative role for platelet factor 4 
(PF4) in the stabilization and binding of dimeric 2GPI /anti-2GPI complexes to platelet 
membranes [40,41]. 
Many serine proteases that function in maintaining hemostasis are targets of autoantigens in 
APS patients. These include activated protein C (APC), prothrombin, antithrombin (AT) and 
many coagulation factors including factors IXa, IIa and II [42]. There is evidence to suggest 
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that antibodies directed against AnnA5, an abundant cationic protein that functions as a 
natural anticoagulant especially in placental tissue, can cause placental thrombosis and fetal 
resorption in mice, although there is conflicting evidence of the significance of these 
antibodies in APS patients [43,44]. A recently described protein antigenic target, vimentin, 
has been suggested to play a putative role in platelet and leukocyte activation in APS 
patients but further characterization of the role of this cytoskeletal protein is necessary [45]. 
5. Origins of APS: Infection-associated APS and molecular mimicry 
The failure of normal T cell tolerance mechanisms seems to be an important component for 
the development of autoimmunity in several diseases. In APS, there is evidence to suggest 
that molecular mimicry can induce production of pathogenic APL antibodies, presumably 
because of a breakdown in normal peripheral tolerance mechanisms [46]. Although aPL 
were first characterized by their ability to bind CL, it is now well accepted that these 
antibodies recognize various PL and protein antigenic complexes [1,2].  
Indeed, efforts to induce high titer production of pathogenic aPL in animal models 
succeeded only after immunization with heterologous 2GPI rather than pure phospholipids 
[47]. This led researchers to believe that perhaps in vivo binding of foreign PL-binding 
proteins resembling 2GPI to self phospholipids in APS patients may lead to the formation 
of immunogenic complexes, against which aPL antibodies are produced. Gharavi et al in 
1999 synthesized a 15 amino acid peptide, GDKV, which spanned an area of the fifth 
domain of 2GPI known to be a major PL-binding site of the molecule, and demonstrated 
the peptide’s ability to induce pathogenic aPL and anti-2GPI antibody production in mice 
[48]. A monoclonal antibody with aPL and anti-2GPI activity generated from these GDKV-
immunized mice was shown to be pathogenic using in vivo models for thrombus 
enhancement and microcirculation [49]. The resulting search for candidate peptides in 
microorganisms that exhibited functional and sequence similarity to the PL-binding domain 
of 2GPI produced the peptides TIFI and VITT from cytomegalovirus (CMV), TADL from 
adenovirus (AdV) and SGDF from Bacillus subtilis. All these peptides had strong similarities 
with GDKV and induced high titers aPL and anti-2GPI production in mice. Subsequent in 
vivo and in vitro experiments confirmed the pathogenicity of antibodies induced in TIFI-
immunized mice [50-52]. 
Further supporting evidence for molecular mimicry as a possible mechanism for APS 
development was provided by a study evaluating the APS-related pathogenic potential of 
microorganisms carrying sequences related to a hexapeptide, TLRVYK, known to be 
specifically recognized by a pathogenic monoclonal anti-2GPI Ab [53]. Following 
immunization with Haemophilus influenzae, Neisseria gonorrhoeae or tetanus toxoid; high titers 
of antibodies of anti-peptide (TLRVYK) and anti-2GPI activity were observed in BALB/c 
mice. These affinity-purified antibodies were then infused into naive mice at day 0 of 
pregnancy. At day 15, these mice had significant thrombocytopenia, prolonged activated 
partial thromboplastin times (aPTT) and increased frequency of fetal loss compared to 
controls [53]. 
Infections are thought perhaps to be the most prominent environmental trigger for aPL 
production and APS development. Syphilis was the first infectious disease recognized to be 
linked to aPL production and this infectious type aPL is for the most part non-pathogenic 
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[54]. However, several subsequent reports have shown that many other infections not only 
trigger aPL production but are associated with the development of APS manifestations as 
well [55,56]. CMV, parvovirus B19, Human immunodeficiency virus (HIV), Hepatitis B and 
C viruses, Human T-cell lymphoma/leukemia virus (HTLV) and Varicella Zoster Virus 
(VZV) are just a few of the infectious agents that have reported associations with aPL 
production and APS manifestations [56]. A recent study has demonstrated that protein H of 
Streptococcus pyogenes can bind 2GPI, inducing conformational changes, exposing hidden 
epitopes and in so doing then enable production of anti-2GPI antibodies [57]. 
Rauch et al have recently put forward a hypothesis regarding the dual role of the innate 
immune system in the initiation and progression of APS based on their work. This 
hypothesis highlights the central part played by toll-like receptors (TLRs), especially TLR4, 
in inducing a break in tolerance, aPL production and epitope spread to several autoantigens 
[58]. Utilizing lupus prone mice treated with CMV derived peptides in the presence of TLR7 
or TLR9 agonists and other lupus prone mice deficient in TLR7 or both TLR7 and TLR9, our 
group has demonstrated for the first time that both these TLRs are involved in aPL 
production in 2GPI immunized mice [59]. 
6. Genetics of APS 
Animal models and family and population studies have been used to highlight genetic 
associations with APS disease characteristics and the occurrence of aPL antibodies in 
patients. In 1992 Hashimoto et al described an animal model of lupus associated APS in 
NZW x BXSB F1 (W/B F1) male mice that displayed spontaneous production of IgG aCL 
antibodies which exhibit co-factor (2GPI) dependent binding to cardiolipin [60]. 
Interestingly, analysis of the genes utilized in the production of pathogenic aCL in these 
mice showed preferential usage of certain VH (variable region of heavy immunoglobulin 
chain) and VK (variable region of kappa light immunoglobulin chain) genes, whereas other 
non-pathogenic aCL utilize random V gene combinations possibly indicating that 
pathogenic aCL production in these mice is antigen driven rather than germiline encoded 
[61]. Genome-wide analysis using microsatellite markers in these mice and their progeny 
revealed that the generation of each disease character was controlled by two independently 
segregating major dominant alleles producing full expression as a complementary gene 
action. Although there was complete genetic concordance between the occurrence of 
antiplatelet Abs and thrombocytopenia, other disease characteristics were independently 
controlled by different combinations of two dominant alleles suggesting that no single 
genetic factor can explain the pathogenesis of APS [62]. Papalardo et al have recently shown, 
using MHCII deficient mice and MHCII deficient mice transgenic for human MHCII 
haplotypes, that MHCII is necessary for producing aPL after immunization with 2GPI and 
certain haplotypes are more effective than others [63]. 
Since 1980, several studies have described families with high incidences of primary APS 
associated with LA, aCL and other autoantibodies [64-66]. The most consistent HLA 
associations in families with APS are HLA-DR4 and DRw53; other less consistent 
associations include DR7, DQw3, DQw7, A30, Cw3 and B60 [67-70]. In non-familial 
population studies HLA-DR4 and DRw53 were also consistently associated with APS 
disease characteristics in addition to DR7 and DQB1*0302 [71-73]. 
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The occurence of aCL antibodies has been reported in association with DRB1*09 in 
Japanese patients with APS secondary to SLE and with C4A or C4B null alleles in black 
American populations. However, patients in the Hopkins Lupus Cohort who were 
homozygous for C4A deficiency had a lower frequency of aCL and LA than patients 
without this deficiency [74-76]. Other less consistent non-familial HLA associations with 
APS include DRB1*04, DQB1*0301/4, DQB1*0604/5/6/7/8/9, DQA1*0102 and 
DQA1*0301/2 [73,77-79]. Several non-HLA genes associations with increased 
autoantibody production and risk of thrombosis have been described in APS patients. 
Perhaps the most profound is a polymorphism in domain 5 of 2GPI, valine instead of 
leucine at position 247, which is found more frequently in patients with APS than 
matched controls and is associated with anti-2GPI production and increased risk for 
arterial thrombosis in these patients [80]. Other less established genetic associations with 
increased thrombosis in APS include the factor V Leiden mutation, the G20210A 
prothrombin mutation (F2 G20210A) and protein C and S deficiencies [81]. 
7. Pathogenic effects of antiphospholipid antibodies: What we have learned 
from In Vivo animal models? 
a. Animal Models of Thrombosis and Endothelial Cell Activation 
Based on the observation that patients with aCL antibodies appear to get thrombi at 
intermittent intervals, our group hypothesized that these antibodies might only enhance the 
thrombotic process after another inciting agent initiated it. With this in mind, Pierangeli et al 
[82] turned to a mouse model of thrombosis devised by Stockmans et al [83] and modified by 
Barker et al [84] that enables measurement of the dynamics of thrombus formation after this 
is induced by a standardized injury. In a series of experiments, this group of investigators 
found that CD1 male mice, injected with purified immunoglobulins (4 IgG, 3 IgM, 2 IgA 
preparations) or with affinity purified aCL antibodies (2 IgG and 2 IgM) had significantly 
larger and more persistent thrombi compared to mice immunized with immunoglobulins 
from healthy humans. The effect of these Ig preparations was also dose-dependent [85]. In 
collaboration with Dr Pojen Chen (UCLA, Los Angeles, Ca), the group showed also that 
human monoclonal aCL antibodies derived from a patient with the APS had thrombogenic 
properties in vivo [86]. Similarly, mice producing aCL antibodies after immunization with 
┚2GPI or human aPL antibodies also had thrombogenic properties in vivo [87]. Furthermore, 
murine monoclonal aPL and a monoclonal antibody obtained by immmunization with the 
phospholipid-binding domain of ┚2GPI, also showed thrombogenic properties in their 
model [48]. The results of studies utilizing this model showed for the first time that aPL 
antibodies significantly enhance thrombus formation in mice.  
Subsequently, Jankowski et al and Fischetti et al demonstrated the thrombogenic effects of 
monoclonal and polyclonal anti-2GPI in hamsters and rats respectively [88,89]. More 
recently, Arad and colleagues showed in an animal model that affinity purified anti-2GPI 
antibodies induce thrombosis in mice in a dose-dependent manner [90]. Hence, several 
investigators have underscored and confirmed the causal relationship between the presence 
of these autoantibodies and thrombo-embolic complications. In all these models, a priming 
effect (injury, endotoxin, etc.) was needed to induce thrombus formation in addition to aPL 
antibodies injected passively into the animals or induced by active immunization. Not only 
did these models demonstrate “enhanced” thrombus formation compared to controls but 
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also they mimicked what happens in actual APS patients, in whom thrombus formation 
follows a triggering event (trauma, immobilization, infection, etc). 
Antibody mediated endothelial cell activation and injury have been identified as potential 
factors that may be involved in the pathogenesis of thrombosis by aPL. The relationship 
between endothelial cell activation and the thrombotic diathesis in APS could be 
explained by a procoagulant state of the activated endothelium or by the adherence of 
mononuclear cells accompanied by the increased expression of adhesion molecules, such 
as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1) and E-selectin (E-sel). Pierangeli et al have utilized a unique animal model of 
microcirculation that allows one to examine and measure changes in adhesiveness of 
leukocytes in the microcirculation of an isolated cremaster muscle in mice [34], as an 
indication of EC activation in vivo (Figure 2). These parameters include rolling and 
sticking of leukocytes and diapedesis of white blood cells into the tissue from the blood 
vessel, etc. Utilizing this model, those investigators first showed that polyclonal aPL 
antibodies significantly enhance adhesion of leukocytes to endothelium in vivo and that 
this correlated with enhanced thrombosis [34,91]. These effects were observed utilizing 
some human and some murine monoclonal aPL antibodies [92]. 
  
         A.             B. 
Pierangeli et al.  
Fig. 2. In Vivo Model of Endothelium Activation. Mice are injected with aPL antibodies or 
control immunoglobulin twice at 0 and 48 hours. At 72 hours the cremaster muscle of 
anesthetized mice (A) is isolated and the adhesion of leukocytes in 5 postcapillary venules is 
assessed (B). Adhesion is defined as leukocytes that remained stationary for at least 30 
seconds.  
In summary, these animal models of thrombosis and endothelial cell activation have not 
only been useful in demonstrating the pathogenic effects of aPL antibodies and their 
causative role in inducing APS morbidity, but have also been instrumental in dissecting the 
intracellular mechanisms involved, in identifying cellular receptors activated by aPL 
antibodies in vivo and in testing potential new treatments for APS (discussed in detail in 
other sections of this chapter) [37,39,51,93-105]. 
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b. Animal Models of Pregnancy Loss in APS. 
Considerable progress has also been made in developing an in vivo model of pregnancy loss 
related to aPL antibodies in the last 20 years. Gharavi et al first reported that MRL/lpr mice 
with IgG aCL antibodies had smaller litter sizes than controls [106]. However, these lupus 
prone mice produce autoantibodies with multiple specificities and have other clinical 
abnormalities (such as kidney disease), which may account for pregnancy loss.  
In 1990, Branch et al reported that Balb/c mice passively immunized with immunoglobulins 
from patients with the APS had nearly 100% fetal wastage compared to mice passively 
immunized with immunoglobulins from patients with normal human immunoglobulins 
[107]. Subsequently, experiments demonstrated that passive immunization of mice with 
polyclonal or monoclonal IgG aCL antibodies resulted in significant fetal resorption [108]. 
Furthermore, Gharavi and colleagues showed that if aCL antibodies are induced in PL/J 
mice (autoimmune prone mice) the animals showed an increase rate of fetal resorption [109].  
Fishman and colleagues reported that production of IL-3 and GM-CSF is decreased in 
splenocytes derived from their mouse models [110] and that intra-peritoneal administration 
of recombinant IL-3 to pregnant mice resulted in abrogation of fetal loss and 
thrombocytopenia.  
More recently Girardi et al utilized that mouse model to demonstrate the involvement of 
complement activation in aPL-mediated pregnancy morbidity utilizing various mice 
deficient in complement components [96,111]. Furthermore, that group of investigators 
showed that heparin prevents pregnancy loss in mice injected with aPL due to the 
complement inhibitory properties of the drug and not to its anticoagulant effects [112]. 
8. Direct proinflammatory and prothrombotic effects of antiphospholipid 
antibodies on platelets, monocytes and endothelial cells 
The activation of platelets, endothelial cells and monocytes via direct binding of aPL 
antibodies plays an important role in the creation of a proinflammatory and prothrombotic 
phenotype in APS patients. Binding of dimeric 2GPI/anti-2GPI complexes to platelets is 
dependent on exposure of anionic phospholipids, especially phosphatidylserine (PS), on 
platelets, which occurs after stimulation by agonists such as thrombin, collagen, and 
adenosine diphosphate (ADP) [113,114]. Pathogenic aPL enhance the expression of 
GPIIb/IIIa, a major fibrinogen receptor, on platelets and our group has shown that in 
GPIIb/IIIa deficient (3-null) mice and mice treated with a monoclonal anti-GPIIb/IIIa 
antibody there is reduced aPL-mediated thrombus formation [115,116]. Our group has also 
demonstrated that the major intracellular signaling pathway activated by aPL binding to 
platelets is the p38 mitogen activated protein kinase (MAPK) pathway and that subsequent 
phosphorylation of cytosolic phospholipase A2 (cPLA2) results in thromboxane B2 (TXB2) 
production. After initial activation through the p38 MAPK pathway, other MAPK pathways 
in platelets, such as ERK-1 (p44 MAPK) and ERK-2 (p42 MAPK), have a potential secondary 
role in signaling [116]. 
The adhesion molecules VCAM-1, ICAM-1 and E-sel have been shown to be upregulated in 
ECs activated by aPL [34,117,118]. Utilizing ICAM-1, VCAM-1, E-sel and P-selectin (P-sel) 
knockout mice, our group demonstrated the importance of ICAM-1, E-sel, P-sel and VCAM-
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1 in promoting leukocyte adhesion and thrombus formation mediated by human polyclonal 
and monoclonal aPL antibodies [91]. Many groups have also demonstrated the upregulation 
of tissue factor (TF) expression and micro-particle formation with associated increases in 
interleukin-6 (IL-6) and IL-8 secretion in ECs and monocytes treated with aPL [119-122]. 
López-Pedrera et al. showed that aPL could induce TF in monocytes by activating the 
phosphorylation of mitogen-activated protein kinase/extracellular regulated kinase (MEK-
1/ERK) protein, and the p38 mitogen-activated protein kinase (MAPK)-dependent nuclear 
translocation and activation of nuclear factor kB (NFkB)/Rel proteins [123]. Increased 
surface expression of both vascular endothelial growth factor (VEGF) and Flt-1 on 
monocytes and elevated plasma levels of VEGF in APS patients suggests that TF 
upregulation in monocytes may occur as a result of stimulation of the Flt-1 tyrosine kinase 
receptor by VEGF [33]. Many researchers have provided evidence that upregulated TF 
mRNA and antigen expression and TF pathway activation plays a key role in APS 
thrombotic manifestations. Indeed, our group found in an ongoing clinical trial, that mean 
serum levels of soluble TF, tumor necrosis factor- (TNF) and VEGF were significantly 
elevated in APS patients compared to controls and treatment with fluvastatin, a statin with 
efficacy in treating APS, resulted in significant decreases of these pro-inflammatory markers 
in most APS patients [124].  
Role of complement in aPL-mediated thrombosis. 
Complement inhibitors are now being tested in patients with inflammatory, ischemic and 
autoimmune diseases [125-127]. The C5 component of complement is cleaved to form 
products with multiple proinflammatory effects and thus represents an attractive target 
for complement inhibition in immune-mediated inflammatory diseases. Furthermore, C5a 
is the most potent anaphylotoxin and a powerful chemotaxin for neutrophils and 
monocytes, with the ability to promote margination, extravasation and activation of these 
cells. In addition, C5b-9 can also stimulate the release of multiple proinflammatory 
molecules and may well play an important role in inflammation apart form its lytic 
function. Thus, blocking C5b-9 as well as C5a generation may be required for optimal 
inhibition of the inflammatory response. 
At the same time, inhibition of the complement cascade at the level of C5 does not impair 
the generation of C3b through the classical and alternative pathways, preserving C3b-
mediated opsonization of pathogenic microorganisms as well as solubilization of immune 
complexes, needed in a normal immune response. For this reason, therapeutic strategies that 
include C5a and its receptor are considered an especially promising approach to 
complement inhibition. For example, therapy with anti-C5 monoclonal antibody (MoAb) 
has proven effective in preventing collagen-induced arthritis in mice and in ameliorating 
established disease. In other studies anti-C5a MoAb improved endothelial dysfunction in 
cardiopulmonary bypass [125,126,128]. Furthermore, an anti-human-C5 MoAb is in phase II 
studies in patients with rheumatoid arthritis and in phase I studies in patients with active 
lupus nephritis [125]. 
In our own studies anti-C5 MoAb reversed aPL-induced thrombophilia and endothelial cell 
activation in mice [129]. A complement C5a receptor antagonist peptide: AcPhe [Ornithine-
Pro-D-cyclohexylananine-Trp-Arg] (C5aR-AP) has specific anti-C5a effects in rats and has 
been shown to have potent in vivo anti-inflammatory activities in murine models of 
endotoxic shock, renal ischemia-reperfusion injury and the Arthus reaction [130-133]. C5aR-
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AP has also been demonstrated to inhibit effects of C5a on human polymorphonuclear cells 
and human vascular ECs [132]. Coversin (rEV576), a C5 inhibitor isolated from the saliva of 
the tick Ornithodoros moubata, was recently shown by our group to significantly inhibit 
venous thrombosis in the presence of aPL in a mouse model [134]. Coversin has proven to 
be an effective therapeutic agent in preclinical models of myasthenia gravis, Guillain Barré 
syndrome, sepsis and asthma and our results indicate a potential therapeutic role for 
coversin in primary thromboprophylaxis and in preventing the extension of acute venous 
thrombosis in APS patients [134-136]. 
9. Thrombotic and non-thrombotic effects of aPL antibodies associated with 
pregnancy morbidity 
Given the prothrombotic nature of the disease, impairment of maternal-fetal blood exchange 
as a result of thrombus formation in the uteroplacental vasculature was thought to be the 
main pathogenic mechanism underlying pregnancy morbidity in APS [137]. However, there 
is evidence to suggest that placental thrombosis is only partially responsible for APS 
pregnancy morbidity. Despite placental thrombosis and infarction being demonstrated in 
some APS patients with first and second trimester abortions, histological evidence of 
thrombosis in the uteroplacental circulation cannot be demonstrated in the majority of 
placentas from APS patients [138-140]. IgG fractions from LA positive APS patients can 
however induce a procoagulant phenotype with significant increases in thromboxane 
synthesis in placental explants from normal human pregnancies [141]. Interestingly, Rand et 
al have reported significantly lower levels of annexin A5, an important anticoagulant during 
pregnancy, covering the intervillous surfaces of placentas in women with aPL when 
compared to controls [142]. In vitro studies have also demonstrated displacement of annexin 
A5 from trophoblast and endothelial cell monolayers by aPL antibodies while murine 
studies have demonstrated the necessity of this protein in maintaining placental integrity 
[43,143]. Anti-annexin A5 antibodies have been reported in APS patients at frequencies up 
to 30% and several studies have demonstrated the association of these Abs with recurrent 
fetal loss in APS patients [44,144]. 
There is growing evidence for a direct effect of aPL antibodies on trophoblasts supported by 
the fact that 2GPI and anionic PLs are normally expressed on the outer leaflet of 
trophoblast membranes under physiological conditions due to high levels of tissue 
remodeling, also explaining the placental tropism of aPL antibodies[145]. In vitro studies 
utilizing murine and human monoclonal aPL antibodies and polyclonal IgG antibodies from 
APS patients have demonstrated 2GPI dependent binding of these antibodies to 
trophoblast monolayers [146,147]. These aPL antibodies have been shown to react with 
syncytiotrophoblast and to prevent intertrophoblast fusion, trophoblast invasiveness and 
hCG secretion [146,148,149]. Finely tuned regulation of cell surface adhesion and signaling 
molecule expression, activation of matrix metalloproteinases (MMPs), angiogenesis and 
spiral artery transformation characterizes the complex and dynamic process that is 
placentation [150]. Induction by aPL antibodies of abnormal trophoblast expression of 
particular integrins and cadherins potentially affecting decidual invasion has been 
demonstrated in vitro [151]. Anti-2GPI monoclonal antibodies can inhibit the proliferation 
of a human choriocarcinoma cell line and extravillous trophoblast differentiation in vitro and 
endometrial biopsy samples from APS patients with recurrent abortions have shown 
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impaired endometrial differentiation [148,152]. Inhibition of endometrial angiogenesis by 
aPL antibodies has been demonstrated in a recent study assessing in vitro human 
endometrial endothelial cell (HEEC) angiogenesis and in vivo angiogenesis in a murine 
model. Human polyclonal IgG aPL antibodies were shown to significantly decrease the 
number and total length of tubule formation, VEGF and MMP production and NF-B DNA 
binding activity in HEEC and to reduce new vessel formation in inoculated mice [153]. 
There is extensive evidence for an inflammatory component to the pathology associated 
with pregnancy morbidity in APS patients. Polyclonal and monoclonal 2GPI dependent 
aPL antibodies can bind stromal decidua cell monolayers and induce a pro-inflammatory 
phenotype characterized by increased ICAM-1 expression and TNF secretion [154]. 
Diminished expression of the complement regulatory protein DAF (decay accelerating 
factor) has been demonstrated in endometrial biopsy samples from APS patients with 
recurrent pregnancy loss underscoring the importance of complement activation [152]. 
Pregnant mice inoculated with human IgG aPL antibodies from APS patients with obstetric 
APS manifestations had increased rates of fetal resorption, fetal growth retardation and 
extensive placental damage characterized by recruitment of neutrophils, upregulated TF 
and TNF-┙ secretion, decidual focal necrosis and apoptosis, loss of fetal membrane elements 
and complement deposition [96]. These effects were abrogated in mice given inhibitors of 
classical and alternative complement pathways and in mice that were C3, C4 or factor B 
deficient pointing to the involvement of all complement pathways in aPL mediated 
pregnancy morbidity [155,111]. Additional murine studies have demonstrated the 
importance of C5a-C5a receptor interactions, especially on neutrophils and monocytes, in 
inducing TF production, oxidative damage, diminished VEGF levels and subsequent 
placental hypoperfusion and injury, fetal growth restriction and resorption [111,156,157]. 
10. Current and potential new treatments for APS-associated clinical 
manifestations 
The cornerstone of treatment for APS remains conventional anticoagulation. Patients who 
have experienced a venous thromboembolic event (VTE) and are positive for an aPL 
antibody should be treated with an initial course of unfractionated heparin (UFH), low 
molecular weight heparin (LMWH) or pentasaccharide followed by warfarin [158]. The 
initial target intensity of oral anticoagulation is a goal international normalized ratio (INR) 
of 2.0-3.0 [158]. Patients that suffer an arterial thrombotic event on this regimen should be 
treated with higher intensity anticoagulation with a goal INR of >3.0 or standard intensity 
oral anticoagulation (INR 2.0-3.0) in combination with low dose aspirin (LDA). Patients who 
are intolerant of oral anticoagulation (e.g. inability to achieve and maintain target INR, 
excessive anticoagulation or adverse effect of warfarin) may be treated with long-term 
LMWH [159]. Patients who are pregnant should not be treated with warfarin therapy due to 
potential teratogenicity; rather use of LDA in combination with heparin (Rai, 1998) or 
LMWH [160,161]. 
The therapeutic management as well as the prevention of recurrent thrombosis in APS has 
been focused on utilizing anti-thrombotic medications. Recurrences, despite seemingly 
adequate treatment, have been reported and the use of oral anticoagulation at a relatively 
high INR for a long period of time has been associated with a high risk of bleeding, with the 
need for frequent monitoring and patient compliance with diet and lifestyle to optimize the 
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therapy. Moreover, still debated is the approach to patients with aPL antibodies without a 
previous thrombotic event. Some physicians would recommend prophylaxis with low dose 
aspirin although there are no evidence-based data supporting that low dose aspirin alone is 
sufficient for primary thrombosis prophylaxis [162]. It is well known that aPL antibodies 
might be persistently present in the serum of APS patients for long periods of time, but 
thrombotic events do occur only occasionally. It has been suggested that aPL antibodies 
(first hit) increase the thrombophilic threshold (i.e. induce a prothrombotic/ 
proinflammmatory phenotype in endothelial cells), but that clotting takes place only in the 
presence of a second hit or triggering event (i.e.: an infection, a surgical procedure, use of 
estrogens, prolonged immobilization, etc) [89]. Current treatments of thrombosis in APS are 
directed towards modulating the final event or “second hit”. Treatments that modulate 
early effects of aPL antibodies on target cells – i.e. monocytes or endothelial cells - (first hit) 
would be more beneficial and potentially less harmful than current treatments.  
Barriers to the development of new drugs for APS include the multifactorial nature of 
thrombosis, controversies about the strength of association between aPL antibodies and 
thrombotic events, and the fact that the mechanisms of aPL-induced thrombosis are not well 
understood. In the long-term management of APS patients, controlled studies with warfarin 
alternatives and the new anticoagulant agents (such as oral direct and indirect thrombin 
inhibitors) as well as newer therapeutic agents are vital. However, it is possible that the 
current “antithrombotic” approach to aPL-positive patients will be replaced by an 
“immunomodulatory” approach in the future as our understanding of the mechanisms of 
aPL-mediated thrombosis grows. Understanding the molecular mechanisms triggered by 
aPL antibodies and identifying biomarkers released as a consequence of cellular activation 
may help to design new ways to treat clinical manifestations in APS. Based on data from 
mechanistic in vitro and in vivo studies, new targeted treatments may be proposed including: 
specific inhibition of tissue factor, blocking binding of the aPL antibodies to target cells (i.e.: 
platelets, endothelial cells, monocytes, trophoblasts, etc), using p38 MAPK inhibitors, NF-B 
inhibitors or GPIIb/IIIa inhibitors, abrogating the activation of complement, or targeting 
cytokines such as IL-6 and TNF-┙. Most of these have been discussed in other sections of 
this chapter (Table 3). Clinical trials are needed to demonstrate whether any of those new 
therapies are safe and efficacious in APS patients [98,100-103,163-167].  
Statins, hydroxychloroquine and rituximab in APS. 
Three FDA approved drugs – statins, hydroxychloroquine (HCQ) and rituximab – are also 
being considered as possible new treatments for APS-associated clinical manifestations 
based on the effects of these drugs on in vitro and in vivo animal studies.  
a. Statins in APS.  
Statins are potent inhibitors of cholesterol synthesis in the mevalonate pathway. In the 
general population, clinical trials of statin therapy have demonstrated beneficial effects in 
primary and secondary prevention of coronary heart disease as well as ischemic stroke 
[168]. However, their beneficial effects are only partially explained by their ability to lower 
cholesterol levels. Pleiotropic effects of statins have been reported, which include decreasing 
the expression of CAMs in monocytes and affecting leukocyte /endothelial interactions, 
down-regulating inflammatory cytokines in endothelial cells or increasing fibrinolytic 
activity 169-171]. 
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Target or 
Medication 
Supportive Evidence Based on In Vitro 
and/or Animal Studies 
Supportive Evidence 
Based on aPL(+) Human 
Studies 
Tissue Factor (TF)  Dilazep inhibitis aPL-induced TF 
upregulation in monocytes and endothelial 
cells (EC) 
No 
Nuclear Factor 
(NF)-B  
NF-B inhibition decreases aPL-induced 
upregulation of TF in EC and aPL-enhanced 
thrombosis in mice 
No 
P38 Mitogen 
Activated Protein 
Kinase (MAPK)  
P38MAPK inhibition decreases aPL-
induced upregulation of TF in EC, platelet 
activation, and aPL-enhanced thrombosis in 
mice 
No 
Platelet 
Glycoprotein (GP) 
Receptors  
GP receptor antagonists decrease the aPL-
mediated enhancement of platelet 
activation and abrogate aPL-induced 
thrombus formation in mice 
No 
Hydroxychlor-
oquine (HCQ) 
HCQ decreases aPL-induced platelet 
activation, inhibits aPL-mediated 
thrombosis in mice, and protects aPL-
induced displacement of Annexin A5 from 
phospholipids bilayers 
Possibly protective 
against thrombosis in 
lupus patients 
A trial will be started 
Spring 2012 
Statins Statins reverse aPL-induced endothelial cell 
activation and TF upregulation, and 
abrogates enhanced thrombus formation in 
mice 
Statins decrease pro-
inflammatory and pro-
thrombotic markers (pilot 
data, small number of 
patients) 
β2GPI and/or anti- 
β2GPI binding to 
Target Cells 
Peptides that mimic domains of ┚2GPI or 
┚2GPI receptor blockers (e.g., anti-annexin 
A2, anti-TLR4, aPOER2 antagonists) inhibit 
aPL-induced EC activation and/or aPL-
mediated thrombosis in mice.  
No 
Complement  Anti-C5 monoclonal antibody decreases 
aPL-mediated thrombus formation in mice; 
anti- C5aRA peptide inhibits aPL-mediated 
thrombosis and TF expression in mice  
No 
B Cells B-cell activating factor (BAFF) blockage can 
prevent the disease onset in 
antiphospholipid syndrome mouse model 
Rituximab is effective for 
non-criteria aPL 
manifestations based on 
the anecdotal reports 
Table 3. Potential Immunomodulatory Approaches in Antiphospholipid-Antibody (aPL) 
Positive Patients.  
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There have been numerous publications recently on the benefit of statins in the medical 
community following the recent results from the JUPITER study, in which patients with 
normal LDL levels of less than 130 mg/dL and elevated C-reactive protein (CRP), levels 
greater than 2.0 mg/dL, receiving rosuvastatin 20 mg daily experienced significant 
reduction in cardiovascular events, non-fatal myocardial infarction, and non-fatal stroke 
[172]. 
Studies have suggested that fluvastatin has beneficial effects on aPL-mediated pathogenic 
effects. First, one study showed that fluvastatin prevented the expression of CAMs and IL-6 
in EC treated with aPL antibodies [173]. Subsequently, Ferrara et al showed that the 
thrombogenic and pro-inflammatory effects of aPL antibodies in vivo could be abrogated in 
mice fed with fluvastatin for 15 days [97] and this effect was independent of the cholesterol 
lowering effects of the drug. The same group of investigators then showed that fluvastatin 
inhibited the effects of aPL antibodies on tissue factor expression on endothelial cells in vitro 
at doses utilized to reduce cholesterol levels in patients [174]. Furthermore, Martinez et al. 
demonstrated that rosuvastatin decreases VCAM-1 expression by human umbilical vein 
endothelial cells (HUVEC) exposed to APS serum in an in vitro model [175]. 
Subsequently, Murthy et al examined whether proinflammatory/prothrombotic markers are 
elevated in patients with aPL antibodies and whether treatment with fluvastatin has an 
effect on those. (Clinical Trials.gov Identifier: NCT00674297). The preliminary analysis of 
this ongoing pilot study showed that fluvastatin 40 mg daily for 3 months significantly 
reduced the pro-inflammatory and prothrombotic biomarkers IL-6, IL-1┚, sTF, sICAM-1, 
sVCAM-1 and E-selectin in persistently aPL-positive patients with or without SLE [176]. 
Furthemore, utilizing proteomic analysis, Cuadrado et al have shown that inflammatory 
proteins can be reversed following one month of treatment with fluvastatin [177].  
In summary, although statins have been used in primary and secondary cardiovascular 
disease prevention, no conclusive data exist for thrombosis prevention in aPL-positive 
patients. Based on data available, it is conceivable that statins may be beneficial in reversing 
upregulation of TF, CAMs and inflammatory cytokines in EC and monocytes. Upon 
successful completion of clinical trials, in theory, statins might even replace warfarin and 
antiplatelet agents in prevention of recurrent arterial and venous thrombosis, thus 
eliminating the risk of hemorrhagic complications associated with warfarin and enabling 
better life style in these patients. Statins may also serve as an alternative treatment in APS 
patients who experience thrombosis despite adequate anticoagulation with warfarin or with 
antiplatelet agents, or in those with thrombocytopenia in whom warfarin is contraindicated. 
Finally, statins would be an appealing prophylactic therapy in patients with high levels of 
aPL antibodies and without a history of thrombosis. Statins are teratogenic and therefore 
their use in pregnancy is contraindicated. Side effects must be closely monitored, including 
elevated liver function tests and potential hyperglycemia and diabetes mellitus. The use of 
statins in the management of patient with APS needs to be further delineated in well-
designed mechanistic and clinical studies.  
b. Hydroxychloroquine 
Hydroxychloroquine (HCQ) is an antimalarial drug, although the precise mechanism of its 
anti-inflammatory action is not known. In addition to its anti-inflammatory effects, there are 
immunomodulatory effects of HCQ that include increasing the pH of intracellular vacuoles 
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and interfering with antigen processing and inhibiting T-cell-receptor-induced and B-cell-
receptor-induced calcium signaling [178,179]. HCQ also has antithrombotic effects by 
inhibiting platelet aggregation and arachidonic acid release from stimulated platelets [180]. 
In the general population, HCQ has been historically used as a prophylactic agent against 
deep vein thrombosis and pulmonary embolism after hip surgeries [181]. 
HCQ is now considered an essential therapeutic choice in the management of lupus. HCQ 
has been shown to decrease the probability of lupus flares, the accrual of damage, and 
possibly protect SLE patients from vascular and thrombotic events [181-183]. Furthermore, 
HCQ may facilitate the response to other agents in SLE patients with renal involvement. 
More recently, chloroquine and HCQ have been shown to improve survival in a cohort of 
232 SLE patients after adjusting for patient characteristics and disease activity [184]. It has 
been recently suggested that HCQ may affect TLR9 activation and IFN-┙ production and 
this drug is now considered an essential therapeutic choice in the management of lupus. 
In aPL-injected mice, HCQ decreases the thrombus size and the aPL-enhanced thrombus 
formation in a dose-dependent manner [95]. Furthermore, HCQ inhibits the aPL-induced 
expression of platelet GPIIb/IIIa receptor (platelet activation) in a dose-dependent fashion 
[115]. Recently, using 3D atomic microscopy force height images, Rand et al showed that 
HCQ also reverses the binding of aPL-┚2GPI complexes to phospholipids bilayers [185,186]. 
In SLE patients, those receiving HCQ experienced fewer thrombotic events and in the 
Baltimore Lupus Cohort, investigators showed a decreased risk of arterial thrombosis [187]. 
Other investigators demonstrated that HCQ decreases the risk of thrombosis in patients 
with SLE (OR 0.67). In a Cox multiple failure time analysis, HCQ was shown to protect 
against thrombosis and increase survival in patients with SLE. In a cross-sectional study in 
which Erkan et al compared 77 APS patients with previous vascular events (65% had no 
other systemic autoimmune diseases) to 56 asymptomatic (no history of thrombosis or fetal 
loss) aPL-positive patients (18% had no other systemic autoimmune diseases), logistic 
regression analysis suggested that HCQ protects against thrombosis in asymptomatic aPL-
positive individuals [188]. In summary, although there is experimental and clinical evidence 
that HCQ might decrease the incidence of thrombosis in patients with SLE, both detailed 
mechanistic and controlled studies are needed to determine the effectiveness of HCQ for 
primary and secondary thrombosis prevention in patients with APS. At this time, even 
though there are insufficient data to recommend HCQ for primary and secondary 
prevention, it might be reasonable to add HCQ to anticoagulation agents in APS patients 
who develop recurrent thrombosis despite optimum anticoagulation.  
Multiple studies have shown reduction in thrombotic events in SLE patients receiving HCQ 
[189,182]. However, despite some studies showing a sharp contrast to this demonstrated 
protective effect, it appears reasonable that HCQ can be used a second line agent, in 
addition to anti-coagulation, in patients with APS and thrombus. As well, before starting 
therapy, it is important to screen for macular toxicity with visual field and fundoscopic 
examination every six to twelve months.  
A prospective blind-placebo control clinical trial of persistently aPL-positive individuals 
will soon be started by an international multicenter collaborative effort under the auspices 
of APS ACTION (Antiphospholipid Syndrome: Alliance for Clinical Trials and International 
Networking). The primary objective of this trial is to determine the efficacy of HCQ therapy 
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in primary thrombo-prophylaxis in persistently aPL-positive APS patients with no history of 
thrombosis or any other systemic autoimmune disease. 
c. Rituximab. 
Recently, rituximab has been shown to be a good therapeutic agent for life-threatening 
CAPS in a small number of patients [190-192]. Rituximab has been successfully used in case 
reports of patients with aPL and auto-immune mediated thrombocytopenia and hemolytic 
anemia. A systematic review of the off-label use of rituximab in APS revealed the higher rate 
of therapeutic response in patients with APS (92%) [193] and an increasing number of 
similar case reports clearly indicates the need for clinical trials to evaluate the effect of 
rituximab in the treatment of resistant APS. Currently Erkan et al are conducting a RITAPS 
open-label Phase II trial using Rituximab to study patients who are aPL positive and 
resistant to conventional anticoagulation (Clinical trials.gov Identifier: NCT00537290). In 
preliminary results reported at a recent annual meeting of the American College of 
Rheumatology in 2011, the investigators reported that although a net decrease of aPL 
antibody titers was not seen in patients given rituximab, the drug appeared to have an effect 
on improving thrombocytopenia, and skin ulcers accompanied by an overall decrease in 
CD19+ B cells. [194].  
11. Concluding remarks 
Since the mid-1980s, aPL antibodies and their associated clinical manifestations have 
attracted great interest among clinicians and investigators. Indeed, the attention directed to 
aPL often exceeds that for other autoantibodies within the field of autoimmunity; even in 
systemic lupus erythematosus, which is characterized by a multitude of specificities, the 
interest in this serological system remains high.  
A significant amount of knowledge has been gained in the last 20 years with respect to etio-
pathogenesis of this complex disease. In addition, progress has been accomplished on 
standardization of “criteria” aPL tests as well as new emerging tests and methodologies that 
may help to improve the diagnosis of APS. Recently, the improved understanding of the 
intracellular and molecular mechanisms activated during aPL-induced thrombosis has 
enabled investigators to propose new and possibly more effective - with less harmful side 
effects - treatments of APS-related clinical manifestations. Clinical trials for these new 
treatments are urgently needed (some already have been started) to translate bench research 
into new therapies for affected patients.  
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